Evidence map›Paper›PMID 40713773›Full record

ArticleVirology journal2025

Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.

Shu Chang, Guo Xiaojuan, Han Xiaotian, Li Mengzhe, Zhai Chengcheng, Bing Jialuo, Jin Liye, Jiang Yujie, Li Jia, Wang Tangqi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shu ChangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China.
Guo XiaojuanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China.
Han XiaotianSchool of Basic Medical Sciences, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, 050011, China.
Li MengzheSchool of Public Health, Xinxiang Medical University, Xinxiang, 453003, China.
Zhai ChengchengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China.
Bing JialuoSchool of Public Health, Xinxiang Medical University, Xinxiang, 453003, China.
Jin LiyeSchool of Public Health, Xinxiang Medical University, Xinxiang, 453003, China.
Jiang YujieZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Li JiaZhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Wang TangqiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China.
Qi ZhenyongSchool of Public Health, Xinxiang Medical University, Xinxiang, 453003, China.
Zhai DeshengSchool of Public Health, Xinxiang Medical University, Xinxiang, 453003, China.
Deng YaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China. dengyao@ivdc.chinacdc.com.
Lu ZhuozhuangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China. luzz@ivdc.chinacdc.cn.
Tan WenjieNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, China CDC, 155 Changbai Road, Beijing, 102206, China. tanwj28@163.com.

Funding

National Key Research and Development Program of China 2022YFC2304100National Natural Science Foundation of China 82061138008
6 · The paper itself

Abstract

backgroundWest Nile virus (WNV) and chikungunya virus (CHIKV) are zoonotic pathogens transmitted by mosquitoes, which cause significant morbidity and mortality globally. Currently, no human vaccine is available against both WNV and CHIKV.

methodsIn this study, we developed a novel bivalent recombinant human adenovirus type 5 (Ad5)-based vaccine, designated Ad5-WNV-CHIKV, which encodes WNV prM-E and CHIKV E3-E2-6 K-E1 antigens. The expression of the target antigens for WNV and CHIKV was validated through western blotting and an immunofluorescence assay. We subsequently assessed the humoral and cellular immune response in C57BL/6 mice following intramuscular administration of a single dose of Ad5-WNV-CHIKV.

resultsBoth low-dose (2 × 10

conclusionA single dose of the bivalent Ad5-WNV-CHIKV vaccine induced strong neutralizing antibody and cellular immune responses against both WNV and CHIKV in mice. These findings provide a foundation for the development of vaccines targeting WNV and CHIKV. A single dose of vaccine could potentially prevent both diseases.

Indexed as

Chikungunya FeverChikungunya virusImmunity, CellularImmunity, HumoralViral VaccinesWest Nile FeverWest Nile virusWest Nile Virus VaccinesAdenoviridaeAdenoviruses, HumanAnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCD8-Positive T-LymphocytesFemaleAntibodies, NeutralizingAntibodies, ViralAntigens, ViralImmunoglobulin GVaccines, SyntheticViral VaccinesWest Nile Virus VaccinesBivalent adenovirus-vector vaccineC57BL/6 miceCellular immune responseChikungunya virusHumoral immune responseWest Nile virus

Identifiers

PMID40713773
PMCPMC12297724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.